MEM-288, a conditionally replicative adenovirus expressing IFNβ and CD40L, showed tumor shrinkage and immune activation in early trials, with ongoing studies exploring its combination with anti-PD1 immunotherapy. This evidence concerns the gene IFNB1 and neoplasm.